Rules-Based Medicine Gets $1.1M SBIR Grant to Develop 50 Cancer Biomarker Assays

Oct 10, 2007

NEW YORK (GenomeWeb News) — The National Cancer Institute has given Rules-Based Medicine a $1.1 million Phase I/Phase II Small Business Innovation Research contract to develop immunoassays for cancer, the biomarker testing company said today.

Austin, Texas-based RBM said it will use the cash to develop 50 new quantitative, multiplexed immunoassays for cancer-related proteins to add to its Human Multi-Analyte Profile platform.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Getting It Early

Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.

Food Bugs to Meet Sequencers

The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.

From Ancient Bathrooms

Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.

This Week in Nature

In Nature this week: ash dieback disease fungal genome, and more.

Main menu